Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Classical hematology 3

Conditions

Leukemia 7Myelodysplastic Syndromes 5Multiple Myeloma 5Neoplasms, Plasma Cell 4Leukemia, Myelomonocytic, Chronic 4Anemia, Refractory, with Excess of Blasts 4Leukemia, Myeloid, Acute 3Anemia, Refractory 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Promyelocytic, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1

Interventions

Cyclophosphamide 6Cord Blood Stem Cell Transplantation 6fludarabine phosphate 5Cyclosporine 5Mycophenolic Acid 4Whole-Body Irradiation 3Radiotherapy 3Arsenic Trioxide 3Antilymphocyte Serum 3Methylprednisolone 2Methotrexate 2Busulfan 2Azacitidine 2lintuzumab 1fludarabine 1Thiotepa 1Tetradecanoylphorbol Acetate 1Tacrolimus 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Leucovorin 1Hematopoietic Cell Growth Factors 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Cytarabine 1Cholecalciferol 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Anemia, Refractory × Arsenic Trioxide × Clear all
NCT00020969 2020-10-05

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

CTI BioPharma

Phase 2 Terminated
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00234000 2020-07-31

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Jonsson Comprehensive Cancer Center

Phase 1 Terminated
1 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00104806 2018-08-10

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Wake Forest University Health Sciences

Phase 2 Terminated
5 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡